Grow | Extract | Sell
Celadon’s 100,000 sq ft UK facility is licenced by UK regulators to cultivate high-THC cannabis and by MHRA to manufacture cannabinoid API to EU-GMP standard using its proprietary extraction technology. Post-legalisation in 2018 in the UK, cannabis-based medicines can be sold under the “specials” framework.
Grow | Extract | Sell
100,000 sq ft EU-GMP facility in UK
Cultivation of high-THC cannabis
Controlled environment indoor cultivation designed for pharmaceutical-level quality and consistency
Extraction technology and manufacturing of API to EU-GMP standard
Using API to develop novel medicines
Celadon uses indoor cultivation hydroponic system in a fully controlled environment. Ensuring the highest quality and consistent pharmaceutical product.
There is no other cultivation facility of this kind in the UK, and the cultivation has been designed to grow to the highest-industry standard of Good Agricultural and Collection Practices (GACP).
Celadon’s Phase 1 cultivation rooms completed their seventh harvest in June 2022. The Phase 2 cultivation rooms will add significant capacity and aim to be operational in Q1 2023.
The facility is set up to deliver all aspects of the cultivation process; from seeds and tissue culture, to vegetation and flowering, to harvest, through to processing to API.
The cultivation rooms adopt the highest levels of technology, including smart lighting, environmental controls, hydroponic systems and plant/inventory tracking software.
Learn more about Celadon’s technology
Celadon has a proprietary extraction technology that manufactures cannabinoid active pharmaceutical ingredients (APIs), and is one of a small number of companies globally of its kind to be awarded EU-GMP certification for a natural high-THC API.
Celadon’s proprietary API manufacturing process is led by its in-house Production and Quality teams to ensure the highest quality pharmaceutical product.
GMP licencing will enable Celadon to sell its high-THC API into the manufacturing market for the development of pharmaceutical medicines, subject to an update to its existing licence by UK regulators, as well as enable Celadon to use its API in the development of its own finished medicines for both clinical trials and selling under the “specials” framework in the UK.
It will also enable Celadon to partner with world-leading pharmaceutical companies who wish to manufacture cannabinoid-based medicines, whether THC, CBD or other cannabinoids.
Receipt of this milestone licence will enable Celadon to sell its high-THC API into the manufacturing market for: